argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Argenx and Zai Lab announced positive topline results from their Phase 3 ALKIVIA study of VYVGART Hytrulo in autoimmune myositis, with efgartigimod achieving a 15.4-point greater improvement in Total Improvement Score over placebo at Week 52. Argenx reported Q2 2026 net product sales of $1.516 billion, up 60% year over year, and net income of $472 million, while Zai Lab posted revenue of $106.3 million and a net loss of $50.8 million. RBC Capital raised its price target on Argenx to $1,100 from $1,025, and William Blair noted the results boosted confidence in Vyvgart's path in dermatomyositis. Hedge fund positions declined for both companies in Q1 2026, with Argenx held by 42 funds and Zai Lab by 14 funds.
argenx Surges 11.5% After Positive Phase 3 Myositis Data
argenx reported that its ALKIVIA Phase 3 trial of VYVGART Hytrulo in adults with autoimmune myositis met its primary endpoint, with patients showing statistically significant and clinically meaningful improvements in Total Improvement Score over 52 weeks versus placebo and a safety profile consistent with prior studies. This is the first Phase 3 study to show such benefit in immune-mediated necrotizing myopathy, a subtype with no approved targeted therapies, underscoring the potential for VYVGART Hytrulo to address a substantial unmet need across a broad, heterogenous myositis population. The company's narrative projects $9.7 billion revenue and $3.5 billion earnings by 2029, requiring 22.3% yearly revenue growth and about a $1.8 billion earnings increase from $1.7 billion today. Some analysts were already expecting argenx to reach about US$11,000,000,000 in revenue and US$4,500,000,000 in earnings by 2029, so this myositis result may strengthen that more optimistic view or prompt others to reassess how product concentration and future pricing pressure could reshape those forecasts.
argenx announced positive topline results from its Phase 3 ALKIVIA study of efgartigimod in adults with autoimmune myositis, meeting the primary endpoint of mean Total Improvement Score at Week 52 in the combined immune-mediated necrotizing myopathy and dermatomyositis population with a p-value of 0.0011. Patients treated with efgartigimod showed a 15.4-point greater improvement versus placebo, with benefits emerging by Week 4 and sustained through the full year even with steroid tapering. In prespecified subtype analyses, the primary endpoint was also met in immune-mediated necrotizing myopathy patients with a 14.8-point greater improvement, while dermatomyositis patients showed a clinically meaningful 14.5-point improvement that did not reach statistical significance in the smaller cohort. The safety profile was consistent with prior studies, and detailed results will be presented at an upcoming medical meeting.
OmniAb Raises 2026 Revenue Guidance to $32-36 Million
OmniAb reported second quarter 2026 revenue of $13.4 million and raised its full-year revenue guidance to a range of $32 million to $36 million, up from the prior $28 million to $33 million. The company's net loss narrowed to $5.9 million, or $0.05 per share, from $15.9 million a year earlier. OmniAb ended the quarter with 110 active partners and 425 active programs, including new license agreements with argenx and EnRosa Therapeutics. Management highlighted two programs that advanced directly from Phase I to Phase III during the quarter: J&J's Ramantamig and Merck KGaA's precemtabart tocentecan. The company also sold two xPloration instruments, bringing the total in the field to four, and expects year-end cash of $37 million to $41 million.
Argenx to Buy Forte Biosciences for $2.2 Billion in Cash
Argenx SE agreed to buy Forte Biosciences for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, a first-in-class anti-CD122 antibody, to Argenx's immunology pipeline. Both companies' boards have approved the transaction, which is expected to close in the third quarter of 2026. Forte shares soared as much as 42% to $77.86 in premarket trading, while Argenx shares fell as much as 0.9% before paring the loss. Analysts at Van Lanschot Kempen called it the right deal at the right time, and KBC Securities said FB102 has blockbuster potential.
Forte Biosciences agrees to acquisition by argenx via cash tender offer
argenx SE has entered into a definitive agreement to acquire Forte Biosciences through a cash tender offer, with both boards approving the transaction. The deal is expected to close soon, subject to customary conditions, and will result in a change of control for Forte Biosciences, with all remaining shares acquired after completion of the tender. Forte Biosciences shares most recently closed at $76.65, reflecting a very large one-year return of more than seven times its earlier level and a 30-day return of 264.5% amid intense market focus on the acquisition. The stock trades about 4% above the $73.80 analyst target and just below the $77 high target. The acquisition shifts the investment thesis toward deal completion risk and tender offer terms rather than standalone growth potential, with flagged risks including forecast earnings decline, shareholder dilution, high share price volatility, and no meaningful revenue remaining relevant until closing.
argenx to acquire Forte Biosciences for $2.2 billion
argenx has signed a definitive agreement to acquire Forte Biosciences for approximately $2.2 billion in total equity value. The deal, approved by both companies' boards, is expected to close in the third quarter of 2026 and will add Forte's first-in-class anti-CD122 antibody FB102 to argenx's immunology portfolio. argenx will launch a cash tender offer for all outstanding Forte shares at $77 per share, an 86% premium to the volume-weighted average price since positive Phase Ib vitiligo data were announced on July 9. The transaction will be funded entirely from argenx's cash on hand and is not subject to financing conditions. Forte expects to release Phase II data for FB102 in the second half of this year.
Gossamer Bio to File Seralutinib NDA in September, Forte Biosciences Acquired by argenx
Gossamer Bio plans to submit a New Drug Application for Seralutinib to treat pulmonary arterial hypertension in September 2026, while Forte Biosciences has agreed to be acquired by argenx for $77 per share in cash, representing a total equity value of roughly $2.2 billion. Gossamer also regained worldwide rights to Seralutinib from Chiesi and reported cash of approximately $57 million as of June 30, 2026. Entera Bio shares soared over 90% after announcing an oversubscribed private placement expected to generate about $275 million in gross proceeds. Omeros gained more than 15% after AstraZeneca's Ultomiris failed a Phase 3 trial for HSCT-TMA, removing a key competitive threat to Omeros's YARTEMLEA. First Tracks Biotherapeutics rose over 18%, continuing its strong performance since its April 2026 Nasdaq debut.
ASML slides on China chip tool report, Forte Bio surges on Argenx buyout
ASML dropped 8% after The Information reported China began mass production of domestically made deep ultraviolet chipmaking tools. Memory chip stocks were mixed as CXMT soared more than 466% in its Shanghai debut, while SK Hynix fell over 8%, SanDisk slid 11%, and Micron Technology lost 5%. SAP jumped more than 7% after announcing the second part of a 10 billion-euro stock buyback. Forte Biosciences rallied about 40% on a $2.2 billion cash acquisition by Argenx at $77 per share, a 40% premium to Friday's close. Brown-Forman climbed almost 4% after rejecting a $15 billion unsolicited takeover offer from Sazerac at $32 per share. Baker Hughes gained 6% on better-than-expected second-quarter earnings and revenue, while Amkor Technology fell 7% ahead of its quarterly report. D-Wave Quantum added 5% on a partnership with AT&T to use annealing quantum computers for AI, and MapLight Therapeutics plunged 68% after a Phase 2 schizophrenia trial missed its primary endpoint.
Micron, energy, and biotech stocks move premarket on chip debut, oil dip, and Forte buyout
Memory stocks rose broadly after Chinese chipmaker CXMT debuted on the Shanghai public market with its stock surging more than 466%, lifting U.S.-listed peers including Micron Technology which advanced 2.5%. Energy stocks followed oil prices lower after the U.S. and Iran agreed to pause attacks, with Chevron down 2.7%, ExxonMobil down 3.2%, and APA, Devon Energy, and Diamondback Energy each falling around 4%. Forte Biosciences rallied more than 39% on news it will be acquired by Netherlands-headquartered Argenx for $2.2 billion in cash, or $77 per share, a 40% premium to Friday's close. Baker Hughes gained nearly 2.2% after reporting better-than-expected second-quarter earnings and revenue, with the CEO citing favorable fundamentals and reaffirming full-year guidance. D-Wave Quantum rose more than 7% after announcing a partnership with AT&T to use its annealing quantum computers for AI, while IonQ gained nearly 4.5% and Rigetti Computing added 3.8%.
Forte Biosciences surges on argenx buyout, Broadcom gains on Samsung deal, oil stocks slide
Stock index futures edged higher on Monday as a pause in U.S.-Iran military strikes eased fears of a broader Middle East conflict. Forte Biosciences shares jumped 39% after argenx SE agreed to acquire the company for $77 per share in cash, valuing the deal at about $2.2 billion and representing an 86% premium to Forte’s volume-weighted average price since reporting positive Phase 1b vitiligo data on July 9. Broadcom rose 2.5% after Samsung Electronics signed a memorandum of understanding to supply memory and foundry chips through 2030 in a deal valued at over $200 billion, with the memory component focusing on HBM for Broadcom’s next-generation AI accelerators and the foundry part centered on Samsung’s 2-nanometer and below process technologies. General Motors gained 2% as Jefferies upgraded the stock to buy from hold with a $99 price target, citing confidence that 2027 will strengthen the automaker’s position within the U.S. profit oligopoly. Exxon Mobil fell 3% alongside the broader oil and gas sector as crude prices tumbled more than 5% on hopes for a diplomatic solution to de-escalate the conflict and allow shipping to resume through the Strait of Hormuz. Everbright Digital declined 5% after pricing a public offering of 4.29 million ordinary shares at $1.88 per share for total gross proceeds of around $8.07 million, with net proceeds intended for general corporate purposes and working capital needs.
argenx SE reports Q2 GAAP EPS of $7.32, beating estimates by $1.12
argenx SE reported second-quarter GAAP earnings per share of $7.32, surpassing analyst expectations by $1.12. Revenue reached $1.52 billion, a 60% increase year-over-year, exceeding estimates by $90 million. For the first half of 2026, cash flow from operating activities was $0.7 billion, compared to a cash outflow of $0.4 billion in the same period of 2025. As of June 30, 2026, the company held $5.2 billion in total cash, cash equivalents, and current financial assets, up from $4.4 billion at the end of 2025.
argenx posts $1.5 billion in second-quarter product net sales, up 60% year-over-year
argenx reported $1.5 billion in global product net sales for the second quarter of 2026, a 60% increase from the same period last year and 17% growth from the prior quarter. The company launched the expanded label for VYVGART and VYVGART Hytrulo in the U.S. to cover all serotypes of generalized myasthenia gravis, and it expects topline results from the registrational ALKIVIA study in autoimmune myositis in the third quarter and from the EMPASSION study of empasiprubart in multifocal motor neuropathy in the fourth quarter. Total operating income reached $1.5 billion for the quarter, while profit for the period was $472 million, yielding diluted earnings per share of $7.32. Cash, cash equivalents and current financial assets stood at $5.2 billion as of June 30, 2026.
American Kidney Fund Launches New Kidney Transplant Resources
The American Kidney Fund has launched new resources to help kidney transplant patients navigate evaluation, surgery, and recovery. The materials include a downloadable post-transplant guide called Your Guide to Life After Transplant, available in English and Spanish, and an interactive e-learning course titled Step Forward: The Road to Kidney Transplant and Beyond. AKF President and CEO LaVarne A. Burton noted that more than 100,000 Americans are on the organ transplant waiting list, with almost 90% waiting for a kidney. The new guide is a companion to AKF's pre-transplant guide, which was sent to 15,660 financial assistance recipients and resulted in 957 patients receiving transplants. Support for the resources is provided by argenx and Biogen.
argenx to Host Autoimmune Myositis R&D Webinar Today
argenx will host an R&D webinar today, June 23, 2026, at 2:00pm ET, focusing on advancing its FcRn leadership into autoimmune myositis. The event will feature argenx management and scientific leadership alongside key opinion leaders Avery LaChance of Harvard Medical School, Arjun Seth of Northwestern University Feinberg School of Medicine, and Rohit Aggarwal of the University of Pittsburgh. A live webcast will be accessible on the Investors section of the argenx website, with a replay available for approximately one year. Supporting presentation slides will also be posted at the same time.
Chronic Inflammatory Demyelinating Polyneuropathy Market Expected to Grow Through 2036 on Advancing Clinical Research
The chronic inflammatory demyelinating polyneuropathy treatment market is projected to grow positively by 2036 across leading markets, driven by an expanding diagnosed patient population, improved disease awareness, and the anticipated introduction of novel mechanism-based therapies. The United States accounted for the largest market size in 2025 compared with the EU4 countries, the United Kingdom, and Japan. Key companies advancing new treatments include Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, and Takeda, with promising pipeline therapies such as Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, and TAK-411. The prevalence of CIDP is estimated at around 5 to 7 cases per 100,000 individuals in the UK, and the market is seeing increased demand for targeted and long-acting therapies including subcutaneous immunoglobulin formulations and FcRn inhibitors.